Market Place
Sourcing Support
Gan & Lee Pharma Announces Positive Ph 1 Results for GZR18 Tablet
12 Nov 2024 //
PR NEWSWIRE
Gan & Lee Presents Phase 2b Data for GZR18 in Obese Adults
11 Nov 2024 //
PR NEWSWIRE
Chinese insulin maker’s GLP-1 bests Ozempic in ph. 2, company says
15 Oct 2024 //
FIERCE BIOTECH
Gan & Lee Presents GZR4 Insulin Results At EASD 2024
14 Sep 2024 //
PR NEWSWIRE
Gan & Lee Announces Progress on Diabetes and Obesity Treatments at ADA 84th
22 Jun 2024 //
PR NEWSWIRE
Gan & Lee To Present Data On Innovative Products At ADA
17 Jun 2024 //
PR NEWSWIRE
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for GZR18
10 Mar 2022 //
PRNEWSWIRE
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee
16 Oct 2021 //
INDIANWEB2
Gan & Lee to present data at the 57th Annual EASD 2021
08 Sep 2021 //
PRNASIA
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP)
02 Jul 2021 //
PR NEWSWIRE
New data on the insulins Aspart (GL-ASP), Lispro (GL-LIS) and Glargine (GL-GLA)
02 Jul 2021 //
PR NEWSWIRE
Phase 1 Drug Candidate GLR2007 has been Granted Orphan Drug Designation
11 Sep 2020 //
PRNNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.